Doximity (DOCS)
(Delayed Data from NYSE)
$42.86 USD
-1.55 (-3.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $42.92 +0.06 (0.14%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$42.86 USD
-1.55 (-3.49%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $42.92 +0.06 (0.14%) 7:58 PM ET
1-Strong Buy of 5 1
F Value B Growth C Momentum C VGM
Zacks News
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Here's Why You Should Hold Centene (CNC) Stock for Now
by Zacks Equity Research
Strong membership growth, contract wins, accretive acquisitions and the streamlining of businesses poise Centene (CNC) well for growth.
BLCO or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
BLCO vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Doximity (DOCS) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Doximity (DOCS) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 17.65% and 0.78%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Nutex Health Inc. (NUTX) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nutex Health Inc. (NUTX) delivered earnings and revenue surprises of 50% and 1.49%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Charles River Laboratories (CRL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Charles River (CRL) delivered earnings and revenue surprises of 7.34% and 4.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Agilon Health (AGL) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Agilon (AGL) delivered earnings and revenue surprises of 33.33% and 5.25%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
ELV or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ELV vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 29.41% and 3.66%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Doximity (DOCS) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Doximity (DOCS) delivered earnings and revenue surprises of 6.25% and 2.33%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Bright Health Group (BHG) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Bright Health (BHG) delivered earnings and revenue surprises of 12.50% and 8.52%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Surgery Partners (SGRY) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Surgery Partners (SGRY) delivered earnings and revenue surprises of -150% and 0.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Progyny (PGNY) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
Progyny (PGNY) delivered earnings and revenue surprises of 160% and 5.64%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Doximity (DOCS) Q2 Earnings Expected to Decline
by Zacks Equity Research
Doximity (DOCS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AMN or DOCS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
Why Doximity (DOCS) Could Beat Earnings Estimates Again
by Zacks Equity Research
Doximity (DOCS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
AMN vs. DOCS: Which Stock Is the Better Value Option?
by Zacks Equity Research
AMN vs. DOCS: Which Stock Is the Better Value Option?
HealthEquity (HQY) Moves 5.3% Higher: Will This Strength Last?
by Zacks Equity Research
HealthEquity (HQY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.